Kammer Andreas R, Amacker Mario, Rasi Silvia, Westerfeld Nicole, Gremion Christel, Neuhaus Danielle, Zurbriggen Rinaldo
Pevion Biotech Ltd., Rehhagstrasse 79, CH-3018 Bern, Switzerland.
Vaccine. 2007 Oct 10;25(41):7065-74. doi: 10.1016/j.vaccine.2007.07.052. Epub 2007 Aug 14.
The purpose of a vaccine is the induction of effective cellular and/or humoral immune responses against antigens. Because defined antigens are often poor immunogens when administered alone, an adjuvant is required to potentiate the immune response. Most of these adjuvants are designed to induce humoral immune responses, including immunopotentiating reconstituted influenza virosomes (IRIVs). IRIVs are one of the few adjuvants currently licensed for human use with the advantage of an excellent safety profile. To induce a potent cytotoxic T lymphocyte (CTL) immune response CTL epitopes have to be encapsulated into IRIVs. However, the existing encapsulation methods are inefficient or rather laborious. We have developed and characterised a new generation of influenza virosomes (TIRIVs) that induced both, strong CTL and antibody responses against specific antigens of choice. In addition, these virosomes were stabilised and offer the possibility of lyophilisation while retaining all their structural, functional and immunogenic properties after reconstitution. TIRIVs induce strong cellular and humoral immune responses and are a versatile and efficient carrier system with adjuvant properties for a variety of antigens. TIRIVs are not only stabilised but also allow easy formulation of new and/or labile T cell and B cell antigens. Considering their immunogenic properties, their flexibility and their superior storage characteristics TIRIVs provide a versatile technology platform for any vaccination strategy.
疫苗的目的是诱导针对抗原的有效的细胞免疫和/或体液免疫反应。由于单独施用时特定抗原通常是弱免疫原，因此需要佐剂来增强免疫反应。这些佐剂大多旨在诱导体液免疫反应，包括免疫增强重组流感病毒体（IRIV）。IRIV是目前少数被批准用于人类的佐剂之一，具有出色的安全性。为了诱导有效的细胞毒性T淋巴细胞（CTL）免疫反应，CTL表位必须被包裹进IRIV中。然而，现有的包裹方法效率低下或相当费力。我们已经研发并鉴定了新一代流感病毒体（TIRIV），它能诱导针对特定选择抗原的强烈CTL反应和抗体反应。此外，这些病毒体得到了稳定，提供了冻干的可能性，并且在重构后保留了所有的结构、功能和免疫原性。TIRIV诱导强烈的细胞免疫和体液免疫反应，是一种多功能且高效的载体系统，对多种抗原具有佐剂特性。TIRIV不仅稳定，还便于新的和/或不稳定的T细胞和B细胞抗原的配制。考虑到它们的免疫原性、灵活性和卓越的储存特性，TIRIV为任何疫苗接种策略提供了一个多功能的技术平台。
